BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC
BBS-Bioactive Bone Substitutes Plc, Company announcement, Inside information, 31 March 2023 at 7.45 p.m. (EEST)
BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort Global Opportunities PCC
BBS-Bioactive Bone Substitutes Plc (“BBS, “Company”) has today renewed the company's capital facility agreement announced on September 30, 2021 with Riverfort Global Opportunities PCC (“RiverFort”) and the maturity dates of repayment installments have been extended by one year. For the first installment the maturity date is 31 March 2024 (previously 31 March 2023) and for the second it is 22 August 2024 (previously 22 August 2024). Key commercial terms and conditions remain unchanged. The reference price on the outstanding amount is recalculated according to the agreement terms to be now EUR 1.008 per share. Consequently, the fixed conversion price shall be EUR 1.4113 per share.
The issuer shall issue 177,140 warrants to Riverfort with the exercise price of EUR 1.4113 per share and expiry date of March 2027.
RiverFort has decided to convert EUR 50,000 of the loan capital into BBS shares, and in addition, a contract renewal fee (5% of the loan capital, equal to EUR 25,000) will be settled in shares. Consequently, BBS issued RiverFort a total of 84,303 company shares at a price of EUR 0.8897 per share. After the transfers, BBS will hold 425,220 treasury shares.
"Our close cooperation with RiverFort continues, and the new arrangement strengthens our company's working capital and supports the company's goal of receiving the CE marking," says Ilkka Kangasniemi, CEO of BBS.
For more information, please contact:
Ilkka Kangasniemi, CEO,+358 40 7080307,
ilkka.kangasniemi@bbs-artebone.fi
Certified Advisor: Nordic Certified Adviser AB,+46 70 551 67 29,
info@certifiedadviser.se
BBS in brief
BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiology company whose core competence is the development, commercialization and manufacture of easy-to-use bone implants that promote bone formation and healing. Bone substitutes, i.e. implants, are intended for the treatment of various bone damage, bone healing problems and bone diseases instead of autologous and bank bone grafts. BBS aims to become one of the leading players in the field of bioactive implants intended for bone healing problems. The company's head office is located in Oulu, and it employs 20 people.
BBS was founded in 2003, and the company has been listed on Nasdaq First North Growth Market Finland since February 2018.
More information: www.bbs-artebone.fi
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Inside information: Meriaura Group's board has conditionally decided to sell Meriaura's minority ownership to Meriaura Invest to rearrange the group's financing25.4.2024 08:30:00 CEST | Press release
Meriaura Group Plc Company announcement, Inside information 25 April 2024 at 8.30 (CEST) Inside information: Meriaura Group's board has conditionally decided to sell Meriaura's minority ownership to Meriaura Invest to rearrange the group's financing To rearrange the group's overall financing situation, the board of Meriaura Group Plc has made a conditional decision to sell Meriaura Ltd's minority stake to Meriaura Invest Ltd. This would settle Meriaura Invest's EUR 4.4 million loan receivable from Meriaura Group. The decision is still conditional upon approval by the new board to be elected at the Meriaura Group's shareholders' meeting on 3 May 2024. Meriaura Group has borrowed a total of EUR 2.7 million from Meriaura Invest in 2023 and EUR 2.8 million in the current year, primarily to finance the operations of its subsidiary, Meriaura Energy Ltd. These loans have facilitated the delivery of the Bad Rappenau project and covered ongoing operating expenses. The loans have been agreed upo
Kvartalsrapport Q1 2024 – Ett mycket starkt första kvartal där nettoomsättningen ökar med 24%, och EBITDA marginal når 14% (MAR)25.4.2024 08:30:00 CEST | Pressemelding
PRESSRELEASE 2024-04-25 Kvartalsrapport Q1 2024 – Ett mycket starkt första kvartal där nettoomsättningen ökar med 24%, och EBITDA marginal når 14% (MAR) FINANSIELLT SAMMANDRAG Första kvartalet • Nettoomsättningen för kvartalet uppgick till 46 464 (37 587) kSEK • EBITDA (rörelseresultat före avskrivningar) uppgick till 6 493 (-195) kSEK • Resultat efter skatt uppgick till 4 502 (-2 336) kSEK • Resultat per aktie 0,34 (-0,18) SEK VIKTIGA HÄNDELSER I PERIODEN • Inga händelser att rapportera EFTER PERIODEN • Inga händelser att rapportera. VD-kommentar ETT MYCKET STARKT FÖRSTA KVARTAL DÄR NETTOOMSÄTTNINGEN ÖKAR MED 24%, OCH EBITDA MARGINAL NÅR 14% Vi summerar ett fjärde kvartal i rad med kraftfull tillväxt och med stark lönsamhet. Det är glädjande med en positiv inledning av året! Vårt attraktiva röntgensystem i5 driver tillväxt och fortsätter leverera effektivitet och kvalitet som våra kommersiella partners framgångsrikt lyckas sälja in i marknaderna. Vår partner Canon Medical Systems i No
Green Hydrogen Systems and BWSC sign strategic collaboration agreement on green hydrogen projects25.4.2024 08:28:40 CEST | Press release
Press release 03/2024 Green Hydrogen Systems and BWSC sign strategic collaboration agreement on green hydrogen projects Kolding, Denmark, 25 April 2024 — Green Hydrogen Systems A/S and BWSC, an international engineering company and service provider, have signed a strategic collaboration agreement to expand their current collaboration on advancing green hydrogen projects. This strategic collaboration agreement is a continuation of the collaboration between Green Hydrogen Systems and BWSC on the installation of the X-Series prototype at GreenLab in Skive, Denmark. This joint installation project, initiated in April 2023, covered initial site layout and site preparation as well as installation of Green Hydrogen Systems' 6 MW HyProvide X-Series prototype module. The 6 MW HyProvide X-Series prototype module is now in operation and producing green hydrogen. With this collaboration Green Hydrogen Systems and BWSC aim to offer full hydrogen plants with pre-engineered and optimised site layout
DOVRE GROUP TRADING STATEMENT JANUARY 1 – MARCH 31, 202425.4.2024 08:15:00 CEST | Press release
Dovre Group Plc Stock exchange release April 25, 2024, at 9.15 a.m. DOVRE GROUP TRADING STATEMENT JANUARY 1 – MARCH 31, 2024 Significant write-down of a single renewable project led to a negative operating profit Dovre Group Plc issues today a trading statement for the three months ended on March 31, 2024.The figures presented in this trading statement are not audited. Last year’s corresponding period in parentheses. January – March 2024 Net sales EUR 42.3 (45.8) million – decrease 7.6% Project Personnel: net sales EUR 25.2 (24.8) million – increase 1.7%Consulting: net sales EUR 3.6 (5.1) million – decrease 29.6%Renewable Energy: net sales EUR 13.5 (15.9) million - decrease 15.1%EBITDA EUR -4.6 (1.9) million Operating result EUR -4.9 (1.7) million Result before tax EUR -5.1 (1.5) million Result for the shareholders of the parent company EUR -2.4 (1.0) millionEarnings per share EUR -0.023 (0.010) Net cash flow from operating activities EUR -1.9 (4.3) million Dovre Group’s profitability
UPM Interim Report Q1 2024: A positive start to the year, growth investments contributed to earnings25.4.2024 08:05:00 CEST | Press release
UPM-Kymmene Corporation Stock Exchange Release (Interim Report) 25 April 2024 at 09:05 EEST UPM Interim Report Q1 2024: A positive start to the year, growth investments contributed to earnings Q1 2024 highlights Sales decreased by 5% to EUR 2,640 million (2,787 million in Q1 2023)Comparable EBIT decreased by 6% to EUR 333 million, 12.6% of sales (356 million, 12.8%)Operating cash flow was solid at EUR 335 million (714 million), including seasonal increase in working capitalNet debt was EUR 2,312 million (2,167 million) and the net debt to EBITDA ratio was 1.46 (0.82)Successful margin management and recovering market demand continued in most businessesUPM Paso de los Toros pulp mill reached positive Q1 EBIT, production at 83% of capacitySale of the Steyrermühl site, Austria in JanuaryCDP recognised UPM with double ‘A’ score for transparency on climate change and forests Key figures Q1/2024Q1/2023Q4/2023Q1–Q4/2023Sales, EURm 2,640 2,787 2,531 10,460Comparable EBITDA, EURm 489 477 465 1,5